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Abstract
Background: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of atherosclerotic vascular
disease, but it is unknown whether the other way around is true too. C57BL/6 (B6) and BALB/cJ (BALB) are two
mouse strains that differ markedly in their susceptibility to atherosclerosis. In this study we investigated the
development of diet-induced T2DM in these two strains.
Methods and Results: When deficient in apolipoprotein E (apoE
-/-) and fed a Western diet for 12 weeks,
atherosclerosis-susceptible B6 mice developed significant hyperglycemia. In contrast, atherosclerosis-resistant BALB
apoE
-/- mice had much lower plasma glucose levels than B6.apoE
-/- mice on either chow or Western diet and
during an intraperitoneal glucose tolerance test. In response to glucose BALB.apoE
-/- mice displayed both the first
and second phases of insulin secretion but the second phase of insulin secretion was absent in B6.apoE
-/- mice. In
response to insulin B6.apoE
-/- mice showed a deeper and longer-lasting fall in blood glucose levels while BALB.
apoE
-/- mice showed little reduction in glucose levels. Pancreatic islet area of BALB.apoE
-/- mice on light
microscopy nearly doubled the area of B6.apoE
-/- mice. Most circulating proinflammatory cytokines were lower in
BALB.apoE
-/- than in B6.apoE
-/- mice on the Western diet, as determined by protein arrays. Increased macrophage
infiltration in islets was observed in B6.apoE
-/- mice by immunostaining for Mac2 and also by flow cytometry.
Conclusion: This study demonstrates that defects in insulin secretion rather than defects in insulin resistance
explain the marketed difference in susceptibility to T2DM in the B6.apoE
-/- and BALB.apoE
-/- mouse model. A
smaller islet mass and more prominent islet inflammation may explain the vulnerability of B6.apoE
-/- mice to diet-
induced diabetes.
Background
Atherosclerosis is the principal cause of morbidity and
mortality among individuals with diabetes [1,2]. The risk
of coronary heart disease is two to four times higher in
diabetic patients than in non-diabetic individuals [3].
Coronary heart disease, stroke, and peripheral arterial
disease also occur at an earlier age in diabetic patients
than in the general population [4]. Diabetic patients
often have dyslipidemia, which is a key factor in the
development of atherosclerosis [5], and exhibit an
atherogenic lipid profile, including an enrichment of tri-
glycerides in the HDL core [6] and an increase in small-
dense, triglyceride-rich LDL particles [7].
Recent studies suggest that dyslipidemia, which com-
prises elevated triglyceride and LDL cholesterol levels
and reduced HDL cholesterol levels, may contribute to
the pathogenesis of T2DM. Supporting evidence
includes observations that dyslipidemia often precedes
T2DM for years, suggesting that disturbances in lipo-
proteins may initiate the pathological process leading to
diabetes [8,9]. Individuals with low HDL have an
increased risk of developing T2DM [8]. On the other
hand, aerobically trained individuals have high HDL and
display enhanced glucose tolerance [10]. Bezafibrate,
which raises HDL levels by 16% and decreases triglycer-
ide levels by 24%, delays the onset of T2DM and
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ary artery disease [11].
One commonly used mouse model of dyslipidemia is
the apolipoprotein E-deficient (apoE
-/-)m o u s e ,w h i c h
exhibits the typical features of dyslipidemia seen in
humans, including elevations in LDL cholesterol and tri-
glyceride levels and reductions in HDL cholesterol levels
[12,13]. Moreover, apoE
-/- mice develop all phases of
atherosclerotic lesions, progressing from the early foam
cell stage to the advanced stage with a fibrous cap and
necrotic lipid core [14]. Recently, we have found that
apoE
-/- mice on the C57BL/6 (B6) genetic background
develop significant hyperglycemia when fed a Western-
type diet [15]. As atherosclerotic cardiovascular disease
is the leading cause of morbidity and mortality among
patients with diabetes, apoE
-/- mice are obviously a
more suitable model for studying diabetes than mice
that do not develop atherosclerosis.
We and others have reported that genetic back-
g r o u n d sh a v ead r a m a t i ci n f l u e n c eo nd y s l i p i d e m i a
[12,16,17]. BALB.apoE
-/- mice have much higher HDL
cholesterol levels than B6.apoE
-/- mice, especially when
fed a high fat diet, although their non-HDL cholesterol
and triglyceride levels are comparable [16]. BALB.
apoE
-/- mice also have lower levels of circulating
VCAM-1 and P-selectin than B6.apoE
-/- mice on either
chow or high fat diet [16]. Thus, we reasoned that
BALB.apoE
-/- mice would be less susceptible to diabetes
than B6.apoE
-/- mice due to their higher HDL and low
inflammation. To test this hypothesis, in the present
study we examined the development of diet-induced
T 2 D Mi nt h et w os t r a i n sa sw e l la sp o t e n t i a lc o n n e c -
tions with inflammation.
Methods
Mice
Female B6.apoE
-/- mice were purchased from the Jack-
son Laboratory. Female BALB.apoE
-/- mice at the N12
generation were generated in our laboratory using the
classical congenic breeding strategy [18]. At 6 weeks of
age, mice continued with a chow diet for additional 6
weeks, or were switched onto a Western diet containing
21% fat, 0.15% cholesterol, 34.1% sucrose, 19.5% casein,
and 15% starch (TD88137, Harlan Laboratories) and
maintained on the diet for 1 2w e e k s .T h em i c ew e r e
housed in a 12 h light-12 h dark cycle pathogen-free
facility at the University of Virginia. All procedures were
carried out in accordance with current National Insti-
tutes of Health guidelines and approved by the Univer-
sity of Virginia Animal Care and Use Committee.
Measurements of plasma glucose and insulin
Mice were fasted overnight before blood was collected
through retro-orbital venous plexus puncture with the
animals under isoflurane anesthesia. Plasma glucose was
measured with a Sigma glucose (HK) assay kit, and insu-
lin was measured with an ultra-sensitive ELISA kit from
Crystal Chem INC.
Glucose tolerance test (GTT) and insulin tolerance test
(ITT)
GTT was performed as described by McDuffie et al [19].
Briefly, overnight fasted mice were subject to an intra-
peritoneal injection of 1 g glucose/kg body weight.
Blood glucose levels were measured with an UltraTouch
glucometer using the whole blood taken from cut tail
tips immediately before and at 10, 20, 30, 60, 90, and
120 min after the injection of glucose. ITT was per-
formed on non-fasted mice by an intraperitoneal injec-
tion of 0.75 U insulin/kg body weight. Blood glucose
was also monitored as above immediately before and at
15, 30, 45, and 60 min after insulin injection.
Glucose-stimulated insulin secretion
After being fasted overnight, mice were injected intra-
peritoneally with glucose (1 g/kg). Blood samples were
collected from cut tail tips immediately before and at
15, 30, 60, and 120 min after the injection of glucose.
Insulin concentrations in the blood were measured with
the insulin kit from Crystal Chem INC.
Plasma cytokine assay
Plasma cytokine levels of mice were analyzed using
mouse cytokine arrays, which contain 144 different
anti-cytokine antibodies and positive and negative con-
trols (RayBiotech). Four separate plasma samples were
pooled in an equal amount from 3 or 4 individual
mice of each group, and each sample was incubated
with one set of arrays. The assays were performed
according to the manufacturer’s instructions. The
intensity of each spot on the arrays was quantified
with a densitometer.
Histological and immunohistochemical analyses
Mouse pancreas was harvested and processed as pre-
viously reported [20]. Briefly, the pancreas was fixed
in 4% paraformaldehyde for > 24 h, then infiltrated
overnight in 30% sucrose, and embedded in Tissue-
Tech OCT compound. Cryosections (8-μmt h i c k )w e r e
collected every 3 sections throughout the pancreas,
and 4 sections were mounted on one slide. Every 5
slides were stained with haematoxylin and eosin
(H&E), and the surface areas of all islets on one sec-
tion per slide were counted for each mouse. The pre-
sence of macrophages in the islets was detected with a
rat monoclonal antibody against mouse macrophages
(MOMA-2) from Serotec, as we previously reported
[21,22].
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Pancreatic islets were prepared using the method of Li et
al [23] with a minor modification. Briefly, the pancreas
was perfused in situ, first with PBS through the heart and
then with a solution containing collagenase XI (1,000 U/
ml) through the common bile duct. Then the entire pan-
creas was isolated and further incubated in the collage-
nase XI-containing solution at 37°C for ~15 min.
Digested pancreas was filtered through a 70-μmn y l o n
cell strainer. The captured islets were further digested
into individual cells with a mixture of 500 U/ml collage-
nase XI and 500 U/ml collagenase I in the Hanks’ salt
solution at 37°C for 15~20 min. As the number of cells
yielded from an individual pancreas was limited, islet
cells were pooled from preparations of 2 or 3 mice.
Islet cells were incubated for 30 min on ice with the
following fluorophore-conjugated primary antibodies
(eBioscience, Inc): FITC-conjugated anti-CD4, pacific
blue (PB)-conjugated CD8a, phycoerythrin (PE)-conju-
gated anti-Mac-3, allophycocyanin (APC)-conjugated
anti-CD11b, and pre-captopril (preCP)-conjugated anti-
CD45. Stained cells were fixed in 2% paraformaldehyde
and then analyzed on a FACSCalibur flow cytometry
using FlowJo software. The macrophage content was
defined as cells double positive for CD11b and Mac3 on
a CD45-positive gate. Lymphocytes were identified as
cells positive for CD4 or CD8 on a CD45-positive gate.
Statistical analysis
Values were expressed as means ± SE, with n indicating
the number of animals. AVOVA or Student’s t test were
used for determining statistical significance between
groups. Differences were considered statistically signifi-
cant at P < 0.05.
Results
Fasting plasma glucose levels of female B6.apoE
-/- and
BALB.apoE
-/- mice were measured when mice were fed a
c h o wo rW e s t e r nd i e t .A ss h o w ni nF i g u r e1 ,B A L B .
apoE
-/- mice had significantly lower levels of fasting
plasma glucose than B6.apoE
-/- mice on both chow (103.6
± 10.9 vs. 142.0 ± 10.7 mg/dl; P =0 . 0 3 1 )a n dW e s t e r n
diets (176.9 ± 25.6 vs. 287.2 ± 17.2 mg/dl; P =0 . 0 0 6 ) .
Compared to the chow diet, the Western diet led to signif-
icant elevations in fasting glucose levels of both B6.apoE
-/-
(P = 0.00016) and BALB.apoE
-/- mice (P = 0.034).
Glucose tolerance test (GTT) and insulin tolerance
test (ITT) were performed on mice fed the Western
diet. As shown in Figure 2, blood glucose levels over the
entire time course of GTT were lower in BALB.apoE
-/-
mice than in B6.apoE
-/- mice (P = 0.000002). Both the
rise and the fall of blood glucose levels were slower in
BALB.apoE
-/- than in B6.apoE
-/- mice. In response to
insulin, B6.apoE
-/- mice showed a deeper and longer-
lasting fall in blood glucose levels while BALB.apoE
-/-
mice displayed little reduction in glucose levels. In addi-
tion, the baseline level of non-fasting blood glucose (at
0 min on ITT) was significantly lower in BALB.apoE
-/-
than in B6.apoE
-/- mice (104.8 ± 4.2 vs. 170.5 ± 18.0
mg/dl; P = 0.038).
Glucose-stimulated insulin secretion was determined
on B6.apoE
-/- and BALB.apoE
-/- mice fed the Western
Figure 1 Fasting plasma glucose levels of female B6.apoE
-/- and BALB.apoE
-/- mice when fed a chow or Western diet. Results are means
± SE of 5 and 7 mice. Mice continued with a chow diet, or were switched onto a Western diet at 6 weeks of age and maintained on the diet
for 12 weeks. * P < 0.05 vs. B6 mice, and
+ P < 0.05 vs. chow diet.
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toneal injection of glucose (1 g/kg), and blood samples
were collected from cut tail tips. Following glucose
injection, BALB.apoE
-/- mice displayed both the first
phase and the second phase of insulin secretion. In con-
trast, the second phase of insulin secretion was not evi-
dent in B6.apoE
-/- mice (Figure 3). Also, at all the time
points assessed, blood insulin concentrations were
higher in BALB.apoE
-/- mice, and the differences were
statistically significant (P = 0.0013).
The total surface areas of islets on H&E-stained sec-
tions intervaled approximately at 500 μma c r o s st h e
entire pancreas were measured. BALB.apoE
-/- mice had a
significantly larger islet surface area than B6.apoE
-/- mice
on the Western diet (1,361,876 ± 81,840 vs. 742,591 ±
47,578 μm
2; P = 0.0013) and had a trend toward larger
islet surface area than B6.apoE-/- mice on the chow diet
(1,264,554 ± 144,838 vs. 716,558 ± 40,582 μm
2; P =
0.068) (Figure 4). The Western diet feeding had no influ-
ence on islet surface area in either strain (P > 0.5).
At 12 weeks of age on the chow diet, BALB.apoE
-/- mice
had a body weight comparable to B6.apoE
-/- mice (18.9 ±
0.7 vs. 17.6 ± 0.9 g; P = 0.30) (Figure 5). However, after
being fed the Western diet for 12 weeks, BALB.apoE
-/-
mice had a significantly larger body weight than B6.apoE
-/-
mice (24.5 ± 0.5 vs. 18.4 ± 0.5 g; P < 0.0001). The body
weight of BALB.apoE
-/- mice fed the Western diet was sig-
nificantly larger compared to those fed the chow diet (P <
0.0001). By contrast, the body weight of B6.apoE
-/- mice
did not differ statistically between the two different diets.
Plasma cytokine levels in B6.apoE
-/- and BALB.apoE
-/-
mice were evaluated using RayBio mouse cytokine antibody
arrays (Figure 6, Additional File 1, Table S1). On the chow
diet, B6.apoE
-/- mice had higher levels of IGFBP-6, IL-12,
LIX, L-selectin, MIP-2, P-selectin, sTNF RI, IGFBP-2,
MMP-3 and osteoponin than BALB.apoE
-/- mice, and
BALB.apoE
-/- mice had higher levels of IGF-I, resistin, dec-
orin, galectin, pentraxin 3, and TWEAK R than B6.apoE
-/-
mice. On the Western diet, B6.apoE
-/- mice displayed
higher plasma levels of AXL, CXCL16, eotaxin-2, IL-12,
TCA-3, sTNF RI, E-selectin, FcG RIIB, ICAM-1, IGFBP-2,
MMP-3, osteoponin, resistin,A C E / C D 1 4 3 ,E - c a d h e r i n ,
galectin, HAI-1, and pentraxin 3 than BALB.apoE
-/- mice,
while BALB.apoE
-/- mice only displayed higher levels of
MIP-2, IGF-I, and TWEAK R than B6.apoE
-/- mice.
Immunohistochemical analysis with an antibody
against MOMA2 showed that the islets of B6.apoE
-/-
mice fed a chow diet had no macrophages (Figure 7).
However, in the pancreas of B6.apoE
-/- mice fed the
Western diet, macrophages were observed within and
around the islets. To accurately quantitate relative
macrophage abundance, we analyzed the proportion of
macrophages and lymphocytes in isolated islet cells by
flow cytometry. Macrophages were identified as CD11b
and Mac3 double positive cells. On the chow diet, only
1.29% living islet cells were macrophages, while on the
Western diet macrophages accounted for 7.72% of the
total living islet cells (Figure 8A, B). Few lymphocytes
were detected in the islets of B6.apoE
-/- mice fed either
a chow or Western diet.
Discussion
Although T2DM is a well recognized risk factor for
atherosclerotic vascular disease, it is unclear whether
Figure 2 Glucose tolerance test (GTT) and insulin tolerance test (ITT) for B6.apoE
-/- and BALB.apoE
-/- mice fed a Western diet. For GTT,
overnight fasted mice were subject to an intraperitoneal injection of glucose (1 g/kg). ITT was performed by an intraperitoneal injection of
insulin (0.75 U/kg) to non-fasted mice. Blood glucose concentrations were determined with a glucometer using blood taken from cut tail tips at
the indicated time points. Values are means ± SE of 4 or 5 mice. * P < 0.05 vs. B6 mice.
Li et al. Cardiovascular Diabetology 2011, 10:117
http://www.cardiab.com/content/10/1/117
Page 4 of 10individuals who are susceptible to atherosclerosis would
have an increased tendency to develop T2DM. We have
now examined this using two mouse strains that differ
markedly in susceptibility to atherosclerosis. Clear differ-
ences have been observed between the two apoE
-/-
mouse strains in blood glucose levels under both fasting
and non-fasting conditions and during the glucose toler-
ance test. Atherosclerosis-susceptible B6.apoE
-/- mice
developed significant hyperglycemia on the high fat diet,
whereas atherosclerosis-resistant BALB.apoE
-/- mice did
not.
B6 and BALB are two inbred mouse strains that have
been studied as a genetic model of atherosclerosis.
When fed an atherogenic diet containing high fat, high
cholesterol, and cholate, B6 mice readily develop fatty
streak lesions in the aortic root, whereas BALB mice are
highly resistant to lesion formation [24,25]. However,
the cholate-containing high - f a td i e ti n d u c e sac h r o n i c
inflammatory state, with the expression of inflammatory
and oxidative stress genes in the liver [26,27],
gallbladder [28], and probably other organs or tissues.
To avoid the influence of the cholate diet, we con-
structed BALB.apoE
-/- mice that developed spontaneous
hyperlipidemia and atherosclerosis on a low fat chow
diet [16]. Compared to B6.apoE
-/- mice, BALB.apoE
-/-
mice are highly resistant to atherosclerosis, developing
much smaller lesions. The two apoE
-/- strains have com-
parable non-HDL cholesterol and triglyceride levels, but
HDL cholesterol levels are 2-fold higher in BALB.apoE
-/-
mice on the chow diet and are 15-fold higher on the
Western diet [16]. The high HDL level should contri-
bute, at least partially, to the resistance of BALB.apoE
-/-
mice to diet-induced hyperglycemia.
In the present study, we found that B6.apoE
-/- mice
but not BALB.apoE
-/- mice had defects in insulin secre-
tion on the high fat diet. Insulin secretion in response
to glucose is usually biphasic, consisting of a transient
initial peak of insulin release, followed by a prolonged
second phase. The first phase insulin response was simi-
lar in both strains, but the second phase insulin
Figure 3 Glucose-stimulated insulin secretion in B6.apoE
-/- and BALB.apoE
-/- mice fed a Western diet. Mice were fasted overnight and
then injected intraperitoneally with glucose (1 g/kg). Blood was collected from cut tail tips. Values are means ± SE of 5 mice for each strain.
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-/- mice but not in
B6.apoE
-/- mice. Impaired insulin secretion has also
been observed in wild-type B6 mice when fed a high fat
diet [29-32]. Studies of isolated islets show that insulin
release defects in response to glucose are associated
with impairments in KATP channels and intracellular
calcium flux [31]. However, as B6.apoE
-/- mice become
diabetic only when fed the high fat diet, the diet-
induced inflammation probably have exacerbated the
insulin secretion defect. The feeding of a high fat diet
induces a chronic inflammatory state with expression of
proinflammatory genes and infiltration of macrophages
in local tissues [33]. In this study we have found that
B6.apoE
-/- mice developed more significant
Figure 4 Pancreatic islet surface areas of B6.apoE
-/- and BALB.apoE
-/- mice fed a chow or Western diet. Cryosections of the pancreas
were stained with haematoxylin and eosin. The surface area of all pancreatic islets from sections spaced approximately at 500 μm was measured
for each mouse. Values are means ± SE of 3 to 10 mice. * P < 0.05 vs. B6 mice.
Figure 5 Body weight (g) of B6.apoE
-/- and BALB.apoE
-/- mice on chow or a Western diet. Results are means ± SE of 9 to 17 mice. * P <
0.05 vs. B6.apoE
-/-,+P < 0.05 vs. chow diet.
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-/-
mice, as most differentially expressed proinflammatory
c y t o k i n e sw e r em o r eh i g h l ye x p r e s s e di nB 6c o m p a r e d
to BALB mice. In a previous study, we have also found
that B6.apoE
-/- mice have higher levels of circulating
adhesion molecules than BALB.apoE
-/- mice on the
Western diet [16].
Adhesion molecules and chemokines are associated
with the recruitment of inflammatory cells, a greater
expression of these molecules is expected to lead to
more leukocytes recruited to local tissues. Indeed, we
have observed an increased infiltration of macrophages
in the islets of B6.apoE
-/- mice when fed the high fat
diet. The increased macrophage infiltration in islets has
also been observed in wild-type B6 mice fed a high-fat
diet [34]. As local inflammation damages b cells and
reduces insulin secretion [35], pancreatic islet inflamma-
tion developed on the high fat diet must have contribu-
ted to pancreatic b cell functional failure observed in
B6.apoE
-/- mice.
We found that B6.apoE
-/- mice had an islet mass that
was approximately half the size of BALB.apoE
-/- mice.
Figure 6 Antibody array analysis of plasma cytokine levels in B6.apoE
-/- and BALB.apoE
-/- mice on both chow and Western diets.
Plasma samples were pooled in an equal amount from 3 mice for each group. The potion of each cytokine on the membranes corresponds to
its position as shown in the supplementary table. There are both positive and negative controls on each membrane.
Figure 7 Immunohistochemical analysis of macrophages in the islets of B6.apoE
-/- mice fed a chow or Western diet. Sections were
stained with a rat anti-mouse macrophage antibody for MOMA-2. Mouse aorta with atherosclerotic lesions serves as controls. The top row is
negative controls. Original magnification × 40.
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of B6.apoE
-/- mice to diet-induced diabetes. The total
islet mass was comparable between mice on the chow
diet and those on the Western diet for both strains.
This finding is consistent with the conclusion that
genetic backgrounds determine the size of the endocrine
pancreas in mouse strains [36].
Despite the fact that BALB.apoE
-/- mice displayed sig-
nificant insulin resistance on the Western diet, as
evidenced by the lack of insulin response during the
insulin tolerance test, they did not develop hyperglyce-
mia. As these mice had a higher plasma insulin level,
the normoglycemia appeared to be maintained by a
compensatory increase in insulin output. BALB.apoE
-/-
mice had a larger islet mass, nearly double the size of
B6.apoE
-/- mice, thus they should have a greater secre-
tory capacity to compensate for the insulin resistance.
This observation suggests that insulin resistance alone is
Figure 8 Flow cytometric analysis of macrophages and lymphocytes in the islets of B6.apoE
-/- mice fed a chow (Figure 8A) or Western
diet (Figure 8B). Macrophages were identified as CD11b and Mac3 double positive cells gated for CD45. Lymphocytes were identified as CD4
or CD8 positive cells gated for CD45. Islet cells were stained with anti-CD45, -CD4, -CD8a, -CD11b, and Mac3 antibodies.
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the apoE
-/- model. On the other hand, B6.apoE
-/- mice
did not have insulin resistance, as indicated on the insu-
lin tolerance test, but they developed hyperglycemia,
suggesting that a defect in insulin secretion is essential
for the development of hyperglycemia in this model.
In this study, we found that BALB.apoE
-/- mice but
not B6.apoE
-/- mice exhibited an increase in body weight
on the Western diet. The increased body weight might
contribute to the resistance of BALB.apoE
-/- mice to
insulin. Previous studies have shown that apoE defi-
ciency prevents the development of obesity in B6 mice
and genetically obese Ay mice on a high fat diet [37,38].
As BALB.apoE
-/- mice, which are deficient in apoE,
exhibited an increase in body weight, other mechanisms
contributing to obesity may override the protective
effect of apoE deficiency observed in our experiments.
In summary, we have demonstrated that genetic back-
grounds have a dramatic influence on susceptibility to
diet-induced T2DM in hyperlipidemic apoE
-/- mice.
Defects in insulin secretion but not insulin resistance
explain the susceptibility of B6.apoE
-/- mice to diet-
induced T2DM. The relatively small pancreatic islet
mass and more severe inflammation probably explain
their accelerated islet b- c e l lf u n c t i o n a lf a i l u r eo nt h e
high fat diet. The recent genome-wide association stu-
dies (GWAS) have identified new loci that are impli-
cated in b-cell development and function, highlighting
insulin secretion in the development of T2DM in
humans as well [39]. Pathological studies have revealed
common features, including islet inflammation and b-
cell destruction, in both type 1 and type 2 diabetes
[34,40].
Limitations of the present study
Although this model can explain the high prevalence of
diabetes in atherosclerotic patients, we have not demon-
strated the direct link between atherosclerosis and dia-
betes in the apoE
-/- mice. In a recent study of IGF-II/
LDLR
-/-ApoB
100/100 mice, Heinonen et al [41] have
found that diabetes has little impact on lesion size when
mice developed severe atherosclerosis in the aorta and
the coronary artery. As non-diabetic LDLR
-/-ApoB
100/100
control mice also developed severe atherosclerosis, there
was little room left to demonstrate a further lesion
increase associated with the effect of diabetes. There
was a room when mice develop early or medial stage of
atherosclerosis, but they were not studied. Our data also
do not prove that the current observation is applicable
to the wild-type of mice as they were not studied.
Nevertheless, a previous study has shown that most
wild-type mouse strains, including B6 and BALB, do not
develop significant hyperlipidemia or hyperglycemia on
a high fat diet, although they exhibit increased insulin
release [42].
Additional material
Additional file 1: Plasma cytokine levels of C57BL/6 (B6) and BALB/
cJ (BALB) apoE
-/- mice fed a chow or Western diet as detected by
cytokine arrays. Plasma cytokine levels of B6 and BALB apoE
-/- mice
were analyzed using mouse cytokine arrays from RayBiotech, which
contain 144 different anti-cytokine antibodies and positive and negative
controls. Four separate plasma samples were prepared with each sample
pooled in an equal amount from 3 or 4 individual mice for each group,
and each sample was incubated with one set of arrays. The assays were
performed according to the manufacturer’s instructions. The intensity of
each spot on the arrays was quantified with a densitometer.
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